[Antitumor activity of adriamycin].
D000284:Administration, Oral; D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007928:Lethal Dose 50; D007939:Leukemia L1210 / Q000188:drug therapy; D008113:Liver Neoplasms; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008815:Mice, Inbred Strains; D008937:Mitomycins / Q000627:therapeutic use; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D051381:Rats; D012510:Sarcoma 180 / Q000188:drug therapy; D012517:Sarcoma, Yoshida / Q000188:drug therapy
D008937:Mitomycins; D004317:Doxorubicin; D003520:Cyclophosphamide; D003630:Daunorubicin